Orilissa launch?

When did Orilissa (elagolix) launch?

Orilissa (elagolix) was launched by AbbVie in the United States in 2018 as an oral treatment for women with moderate to severe pain associated with endometriosis. [1]

Who launched Orilissa, and where is it available?

AbbVie is the manufacturer/marketer behind Orilissa’s launch in the U.S. [1]

What does “Orilissa launch” usually refer to (FDA approval vs. market rollout)?

People searching “Orilissa launch” often mean the FDA approval date and first commercial availability. Orilissa entered the U.S. market in 2018 after FDA approval. [1]

Related question: How has Orilissa’s label evolved since launch?

If you meant “launch” as in later labeling changes (safety communications, dosing limits, or restrictions), that goes beyond the initial launch event and depends on the specific update you’re tracking. If you tell me what change you’re looking for (for example, dosing, duration limits, or safety warnings), I can narrow it to the relevant timeline.

Sources

1. https://www.drugs.com/medical-answers/orilissa-when-approved-unknown-1790.html